Taurine

Taurine

SCHEMBL42632

NCCS(=O)(=O)O.NCCS(=O)(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 3/20 1.00
LMNA P02545 2/20 1.00
SLC6A6 P31641 1/20 1.00
CYP2C19 P33261 1/20 1.00
APP P05067 1/20 0.67
PTGS1 P23219 1/20 0.47
PDE4A P27815 1/20 0.47
ALDH1A1 P00352 2/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 2/20 0.38
CA5A P35218 2/20 0.38
CA5B Q9Y2D0 2/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
NT5E P21589 1/20 0.38
CA4 P22748 1/20 0.38
CA6 P23280 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
PMP22 Q01453 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Taurine SCHEMBL30191395 1.00
Taurine SCHEMBL30179154 1.00
Taurine SCHEMBL23068 1.00
Taurine SCHEMBL8052521 0.97 BLM (0.93) BLMLMNASLC6A6CYP2C19APP
Taurine SCHEMBL923628 0.97
Taurine SCHEMBL466027 0.97
Taurine SCHEMBL19438470 0.97
Taurine SCHEMBL3667691 0.97
Taurine SCHEMBL10952596 0.97
Taurine SCHEMBL1100954 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114002421-B Application of exosome metabolite as bipolar affective disorder marker 佛山市第三人民医院(佛山市精神卫生中心) 2022-04-05 CN claimed
CN-114002421-A Application of exosome metabolite as bipolar affective disorder marker 佛山市第三人民医院(佛山市精神卫生中心) 2022-02-01 CN claimed
US-20110092636-A1 WATER SWELLABLE AND WATER SOLUBLE POLYMERS AND USE THEREOF AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2011-04-21 US claimed
JP-5097666-A None JP disclosed
US-20250177330-A1 Use of Thiol Compounds to Treat Neurological Disease MERCAPTOR DISCOVERIES, INC. 2025-06-05 US disclosed
US-12128014-B2 Use of thiol compounds to treat neurological disease MERCAPTOR DISCOVERIES, INC. (US) 2024-10-29 US disclosed
EP-3615013-B1 THIOL COMPOUNS FOR TREATING ACUTE TRAUMATIC BRAIN INJURY MERCAPTOR DISCOVERIES INC (US) 2024-08-14 EP disclosed
WO-2024099769-A1 A METHOD OF EARLY PREDICTION OF RISK OF PRE-TERM PRE-ECLAMPSIA IN SPECIFIC POPULATION COHORTS Metabolomic Diagnostics Limited (IE) 2024-05-16 WO disclosed
US-11958109-B2 Three-dimensional printing HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) 2024-04-16 US disclosed
WO-2024058984-A2 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES MarvelBiome, Inc. (US) 2024-03-21 WO disclosed
EP-4199726-A1 BIOLOGICAL-BASED CATALYST TO DELAY PLANT DEVELOPMENT PROCESSES Crowpierce Technologies, LLC (US) 2023-06-28 EP disclosed
EP-1158972-A1 TREATMENT OF HYPERTENSION WITH COMPOUNDS THAT INHIBIT THE DESTRUCTION OF ENKEPHALINS OR ENDORPHINS Ehrenpreis, Seymour (US) 2001-12-05 EP disclosed
EP-1149878-A2 Ink, ink-jet ink, method for reducing kogation on surface of heater of ink-jet recording head, method for ink-jet recording, ink-jet recording apparatus, recording unit and method for prolonging ink-jet recording head life CANON KABUSHIKI KAISHA (JP) 2001-10-31 EP disclosed
US-6218352-B1 STORAGE STABILITY; WATER SOLUBILITY; AS BLEACHING AGENT ORIENTAL CHEMICAL INDUSTRIES (KR) 2001-04-17 US disclosed
US-6207190-B1 SYNERGISTIC MIXTURE TO REDUCE OCULAR PRESSURE AND IMPROVE VASCULAR HEALTH COMPRISING FOLIC ACID, A MAGNESIUM SALT, ALPHA-TOCOPHEROL, ASCORBATE AND ALPHA-LIPOIC ACID CHRONORX, LLC 2001-03-27 US disclosed
WO-2000041686-A1 TREATMENT OF HYPERTENSION WITH COMPOUNDS THAT INHIBIT THE DESTRUCTION OF ENKEPHALINS OR ENDORPHINS EHRENPREIS SEYMOUR (US) 2000-07-20 WO disclosed
US-5539024-A REACTION PRODUCT OF PERFLUOROALKYL SULFONAMIDE, OXYETHYLENE COMPOUND SUCH AS POLYETHERESTER, AND EPOXY COMPOUND SUCH AS NOVOLAC GLYCIDYL ETHER, PROTECTIVE COATINGS FOR PAPER, TEXTILES, LEATHER, MINERALS BAYER AKTIENGESELLSCHAFT (DE) 1996-07-23 US disclosed
JP-H0597666-A AMPHOTERIC ION COMPOUND AND N-HALO DERIVATIVE OF THE SAME USED FOR THERAPY OF CLINICAL SYMPTOM DERMA SYST LAB LTD 1993-04-20 JP disclosed
US-4565830-A TAURINE AZUMA JUN ICHI (JP) 1986-01-21 US disclosed
US-4563470-A TREATMENT OF METAL DEFICIENCIES LES LABORATORIES MERAM (FR) 1986-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12128014-B2 Use of thiol compounds to treat neurological disease TST, NLN, SLC7A11 BLM 4022/4885LMNA 4730/4885SLC6A6 105/4885
US-20250177330-A1 Use of Thiol Compounds to Treat Neurological Disease TST, NLN, SLC7A11 BLM 4022/4885LMNA 4730/4885SLC6A6 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.